In dogs, supraventricular tachyarrhythmia (SVTA), such as supraventricular tachycardia, atrial fibrillation, or atrial flutter, represents an arrhythmia observed independently or accompanying heart disease and other systemic disorders \[[@r15]\]. In SVTA, supraventricular impulses are transmitted to the ventricles at a high frequency, leading to an increased ventricular rate \[[@r15]\]. A continued increased ventricular rate results in a reduced ventricular systolic function \[[@r23]\]. Furthermore, if the reduction in ventricular systolic function is sustained for a long period, it may cause severe heart failure \[[@r23], [@r35]\]. Therefore, it is important to establish treatments for maintaining a stable ventricular systolic function during long-term therapy of dogs with SVTA.

It has been reported that myocardial injury such as degeneration and fibrosis of the myocardial tissue can be caused by activation of the renin-angiotensin-aldosterone system (RAAS) in animals with SVTA and that pathological changes caused by RAAS over-activation play an important role in the development of ventricular systolic dysfunction \[[@r30]\]. Angiotensin-converting enzyme (ACE) inhibitors (ACEIs) and angiotensin II (ANG II) type 1 receptor (AT1) blockers (ARBs) are known as drug groups that control RAAS activity. ACEIs inhibit the activity of the enzyme that converts ANG I to ANG II and reduce the effects of ANG II, which plays a central role in the RAAS, by decreasing ANG II production. However, in humans and dogs, it was demonstrated that the production of ANG II is supported by mast cell-derived chymase in addition to ACE \[[@r1], [@r28]\]. Therefore, it was suggested that the activity of ANG II cannot be completely inhibited by ACEIs alone. For this reason, ARBs have been developed for use in humans to selectively block AT1 receptors and inhibit ANG II activity at the receptor level \[[@r31]\]. Funabiki *et al*. compared the inhibitory effects of ARBs and ACEIs on myocardial fibrosis in dogs. Their study showed that treatment with either an ARB or an ACEI alone is less effective than the combination therapy. Nevertheless, ARBs are more effective than ACEIs \[[@r9]\]. Ohta *et al*. reported that ARBs show superior effects compared to ACEIs in preventing cardiac contractile dysfunction in dogs with tachycardia \[[@r19]\].

Recently, telmisartan, an ARB, was approved and released in several countries for use as a therapeutic drug in animals and is currently used to treat proteinuria in cats with chronic kidney disease (chronic renal failure). Schierok *et al*. \[[@r20]\] reported that telmisartan was also effective in dogs with renal diseases. A therapeutic effect of telmisartan was also suggested in dogs with chronic kidney disease (chronic renal failure) and its clinical efficacy for the treatment of protein leakage into urine was confirmed \[[@r2]\]. Moreover, telmisartan was reported to exert protective and maintenance effects on ventricular function in a dog model of stunned myocardium \[[@r13], [@r17]\].

The objective of this study was to evaluate the inhibitory effects of telmisartan, an ARB agent approved for animal use, on myocardial injury and the resulting ventricular systolic dysfunction during the development of SVTA in a dog model.

MATERIALS AND METHODS {#s1}
=====================

This study was conducted in accordance with the Ethical Code for Animal Experiments of the Tokyo University of Agriculture and Technology (Approval number: 27-38).

Animals
-------

A total of 14 clinically healthy mature beagles (8 males and 6 females, 2--5 years old, body weight 9--11 kg) were included in this study. Dogs were provided food containing 1.8 × \[70 × (kg body weight) ^0.75^\] kcal/day \[[@r5]\], and water was supplied *ad libitum*. The dogs were individually housed during the study. The environment was maintained at a temperature of 21 ± 2°C and a relative humidity of 50 ± 20%, with a 12 hr: 12 hr light-dark cycle. In addition, the dogs could run freely in a playground for 30 min every day. SVTA canine models with induced artificial tachycardia were prepared by continuously applying high-frequency electric stimulation to the atrium \[[@r8], [@r23]\]. The procedures for developing the SVTA canine models have been described in detail by Ohashi *et al.* \[[@r18]\] and Gaspo *et al*. \[[@r10]\]. Animals were pre-anesthetized using a subcutaneous injection of atropine sulfate at 0.05 mg/kg (Mitsubishi Tanabe Pharma Co., Osaka, Japan) and an intravenous injection of midazolam at 0.2 mg/kg (Dormicum; Astellas Pharma, Tokyo, Japan). Anesthesia was induced using an intravenous injection of propofol at 5--6 mg/kg (Propofol; Fresenius Kabi, Tokyo, Japan) and isoflurane (Isoflur; DS Pharma Animal Health, Osaka, Japan) was administered to maintain anesthesia via an endotracheal tube (end-tidal isoflurane concentration: 1.3--1.7%). A thoracotomy was performed at the fifth intercostal space and an atrial stimulation electrode lead (TY216-033; UNIQUE Medical Co., Ltd., Tokyo, Japan) was sutured to the left atrial appendage. The electrode lead was passed through a subcutaneous tunnel and exposed at the back of the body. The chest was then closed, as done routinely. For perioperative pain management, 0.02 mg/kg of buprenorphine hydrochloride (Lepetan injection, Otsuka Pharmaceutical Co., Ltd., Tokyo, Japan) was intravenously injected pre-operatively and bupivacaine hydrochloride (Marcain; AstraZeneca K. K., Osaka, Japan), and lidocaine (Xylocaine; Aspen Japan, Tokyo, Japan) were administered at the incision area. A meloxicam dose of 0.3 mg/kg (Metacam 0.5%; Boehringer Ingelheim Animal Health Japan Co., Ltd., Tokyo, Japan) was administered subcutaneously at 3 days post-surgery. After the operation, the dogs were placed in a jacket with a pocket in which an external cardiac pacemaker (EV4543; Taisho Biomed Instruments Co., Ltd., Tokyo, Japan) was installed. The recovery period after the surgery was 14 days. The 14 dogs were randomly assigned to either a group that did not receive medication during rapid atrial pacing (RAP) (Control group, n=7) or a group that received telmisartan during RAP (Telmisartan group, n=7). After the recovery period, the electrode leads were connected to the pacemakers in both groups and RAP was initiated; stimulations of 2 Volts were administered at a frequency of 390 beats per min (bpm). The Telmisartan group was orally administered with telmisartan (Semintra; Boehringer Ingelheim Animal Health Japan Co., Ltd.) at 1.0 mg/kg once per day (AM 8:00--9:00) during RAP. The period of RAP was 3 weeks for both groups.

Procedures
----------

We conducted measurements of cardiac troponin I (cTnI) concentration, echocardiography, and blood pressure measurements before starting RAP (Baseline) and 3 weeks after RAP initiation. The examinations after 3 weeks were conducted 1 hr after the temporary pause of RAPs to capture the pathological features of the heart ([Fig. 1](#fig_001){ref-type="fig"}Fig. 1.Schematic outline of study design. Postoperative recovery period was 14 days. Then, measurement of cardiac troponin I concentration, blood pressure measurement, and echocardiography were performed before the initiation of RAP (Baseline) and 3 weeks after the initiation of RAP. Examinations at 3 weeks were carried out 1 hr after RAP was paused. RAP, rapid atrial pacing; bpm, beats per min; W, weeks.). All examinations were performed without the use of anesthetics. Furthermore, to avoid the influence of diurnal variations on the measured values, all experimental procedures were conducted at a fixed time (PM 4:00--5:00).

Ventricular rate
----------------

This parameter was calculated per min using an electrocardiogram (D300; Fukuda M-E Kogyo Co., Ltd., Tokyo, Japan). The ventricular rate during RAP was measured right after and 3 weeks after RAP initiation. All examinations were performed without anesthetics.

cTnI concentration
------------------

Blood samples were collected from the jugular vein in a tube with serum-separating medium and centrifuged at 3,000 rpm for 10 min. Measurement of cTnI concentration was performed by a commercial laboratory (FUJIFILM Monolith, Co, Ltd., Tokyo, Japan). Plasma cTnI concentration was measured using a highly sensitive chemiluminescence enzyme immunoassay (ADVIA Centaur CP TnI-ultra, Siemens Healthineers Japan, Tokyo, Japan). It is a 3-site, second-generation sandwich immunoassay employing direct chemiluminometry; the lower and upper limits of cTnI detection were 0.006 and 50 *n*g/m*l*.

Blood pressure measurements
---------------------------

The systolic arterial pressure (SAP), mean arterial pressure (MAP), and diastolic arterial pressure (DAP) were measured at the tail-head using a noninvasive oscillometric sphygmomanometer for animals (BP-100D; Fukuda M-E Kogyo Co., Ltd.) with a cuff width of 40--60% of the circumference of the measured region \[[@r4]\]. Measurements were obtained in triplicates and, when the errors were within 3 mmHg, the mean value of the 3 measurements was used.

Echocardiography
----------------

The echocardiography was carried out using an ultrasound unit (Logiq 7; GE Health Care Co., Ltd., Tokyo, Japan). The end-diastolic and end-systolic left-ventricular internal diameter (LVIDd and LVIDs, respectively), and the left-ventricular fractional shortening (FS), an index of the left-ventricular systolic function, were measured using the M-mode on the right parasternal short-axis view at the level of the tendinous cord. Heart rates (HRs) were recorded simultaneously. Using the left parasternal apical 5-chamber view, the ratio between pre-ejection period and ejection time (PEP/ET) was determined from the waveform of the left-ventricular outflow tract, wherein the sample volume was set on the closed site of the aortic valve. The PEP was defined as the time interval between the Q wave and the beginning of the ventricular ejection \[[@r7], [@r16]\]. In the same view, cardiac output (CO) and stroke volume (SV) were obtained by measuring the aortic diameter (d) and the velocity time integral (VTI) based on the left-ventricular outflow on pulsed-wave Doppler imaging. The following equations were used: SV=(d/2)^2^ × π × VTI and CO=SV × HR \[[@r7]\].

Echocardiography data were measured over an average of 9 consecutive beats.

Statistical analysis
--------------------

Data were expressed as the mean ± standard deviation. The normal distribution of the measurements was analyzed using the Kolmogorov-Smirnov test. Based on these results, data obtained at baseline and at 3 weeks were statistically analyzed by a paired *t*-test or Wilcoxon signed-rank test for intragroup comparison and by Student's *t*-test or Mann-Whitney *U*-test for intergroup comparison. The statistical analyses were performed using statistical software (BellCurve for Excel; Social Survey Research Information Co., Ltd., Tokyo, Japan), and *P*-values \<0.05 were considered statistically significant.

RESULTS {#s2}
=======

No significant differences between the 2 groups were observed in the baseline measurements of any tested feature.

Ventricular rate
----------------

In the Control group and the Telmisartan group, the ventricular rates were 185 ± 12 bpm and 187 ± 8 bpm immediately after stimulation, and 188 ± 20 bpm and 190 ± 15 bpm at 3 weeks, respectively. No significant differences were observed either within or between the groups.

cTnI concentration
------------------

The cTnI concentration in the Control group increased significantly at 3 weeks after RAP initiation compared with that at Baseline (0.025 ± 0.034 *n*g/m*l* versus 0.159 ± 0.094 *n*g/m*l*) (*P*\<0.01), but no significant difference was observed in the Telmisartan group (0.018 ± 0.029 *n*g/m*l* versus 0.015 ± 0.011 *n*g/m*l*). The cTnI concentration at 3 weeks was significantly lower in the Telmisartan group than in the Control group (*P*\<0.01) ([Fig. 2](#fig_002){ref-type="fig"}Fig. 2.Changes over time of cardiac troponin I concentration in Control and Telmisartan groups. Baseline, before rapid atrial pacing (RAP); 3 W, 3 weeks after RAP; Control, RAP with no medication; Telmisartan, RAP with telmisartan administration; ^\#\#^, *P*\<0.01 versus Baseline; \*\*, *P*\<0.01 versus Control group.).

Blood pressure examination
--------------------------

The SAP was significantly decreased at 3 weeks compared with that at Baseline in both groups (both *P*\<0.01). The MAP was significantly decreased in the Telmisartan group at 3 weeks compared with that at Baseline. By contrast, the MAP in the Control group did not significantly differ between 3 weeks and Baseline. The MAP and DAP values (each *P*\<0.01) at 3 weeks were significantly lower in the Telmisartan group than in the Control group ([Table 1](#tbl_001){ref-type="table"}Table 1.Value of blood pressure measurement parameter in Control and Telmisartan groupsParameterGroupBaseline3 WSAPControl147 ± 19125 ± 17^a)^Telmisartan143 ± 6107 ± 12^a)^MAPControl110 ± 15102 ± 16Telmisartan101 ± 973 ± 14^a,b)^DAPControl92 ± 1991 ± 21Telmisartan82 ± 1360 ± 14^b)^All values are expressed as mean ± standard deviation. SAP, systolic arterial pressure; MAP, mean arterial pressure; DAP, diastolic arterial pressure; Baseline, before rapid atrial pacing (RAP); 3 W, 3 weeks after RAP; Control, RAP with no medication; Telmisartan, RAP with telmisartan administration. a) *P*\<0.01 versus Baseline, b) *P*\<0.01 versus Control group.).

Echocardiography
----------------

The LVIDs was significantly larger in the Control group than in the Telmisartan group at 3 weeks (*P*\<0.01). No significant change was found in the LVIDd of the Control group. By contrast, in the Telmisartan group, a significantly smaller LVIDd was observed at 3 weeks compared with that at Baseline (*P*\<0.01). A significantly larger LVIDs was observed in the Control group at 3 weeks compared to that at Baseline (*P*\<0.01) ([Table 2](#tbl_002){ref-type="table"}Table 2.Values of echocardiographic parameters in Control and Telmisartan groupsParameterGroupBaseline3 WHRControl128 ± 33122 ± 30Telmisartan108 ± 22120 ± 22LVIDdControl31.0 ± 2.229.2 ± 3.5Telmisartan29.0 ± 3.826.9 ± 2.0^a)^LVIDsControl19.2 ± 1.922.5 ± 4.0^a)^Telmisartan17.1 ± 1.818.6 ± 1.5^b)^FSControl38.2 ± 3.823.4 ± 5.6^a)^Telmisartan38.2 ± 5.131.5 ± 6.1^a,b)^PEP/ETControl0.13 ± 0.030.33 ± 0.07^a)^Telmisartan0.12 ± 0.030.19 ± 0.06^a,b)^SVControl17.0 ± 5.810.9 ± 3.4^a)^Telmisartan15.2 ± 5.013.7 ± 4.9COControl1.99 ± 0.481.31 ± 0.34^a)^Telmisartan1.72 ± 0.511.55 ± 0.68All values are expressed as mean ± standard deviation. HR, heart rate; LVIDd, end-diastolic left ventricle internal dimension; LVIDs, end-systolic left ventricle internal dimension; FS, fractional shortening; PEP/ET, pre-ejection period/ejection time; SV, stroke volume; CO, cardiac output; Baseline, before rapid atrial pacing (RAP); 3 W, 3 weeks after RAP; Control, RAP with no medication; Telmisartan, RAP with telmisartan administration; a) *P*\<0.01 vs Baseline, b) *P*\<0.01 vs Control.). FS decreased significantly after RAP compared with that at Baseline in both groups. However, FS was significantly greater at 3 weeks in the Telmisartan group than in the Control group (*P*\<0.01) ([Table 2](#tbl_002){ref-type="table"}). The ratio PEP/ET was significantly increased at 3 weeks after RAP initiation compared with that at Baseline, in both animal groups. However, the PEP/ET ratio at 3 weeks was significantly lower in the Telmisartan group compared to that in the Control group (*P*\<0.01) ([Table 2](#tbl_002){ref-type="table"}). The CO and SV values in the Control group were significantly decreased at 3 weeks compared with those at Baseline (both *P*\<0.01), but no significant difference was observed in these values in the Telmisartan group. No significant difference was found in the HR either within or between the groups ([Table 2](#tbl_002){ref-type="table"}).

DISCUSSION {#s3}
==========

In clinical cases, the ventricular rate of dogs with SVTA often increases to values over 200 bpm, and in some cases, this rate exceeds 300 bpm \[[@r15]\]. In this study, the ventricular rates of the Telmisartan group and the Control group during RAP were over 250 bpm, which means that the RAP given was adequate for the establishment of the SVTA model. Moreover, the ventricular rates observed during and after RAP were similar in the Telmisartan group compared with those in the Control group. Therefore, the cardioprotective effect of telmisartan observed in this study does not seem to result from changes in ventricular rate.

The cTnI level is widely utilized as a biomarker for the diagnosis of myocardial infarction in humans \[[@r26]\]. cTnI is a myocardial intracellular protein that is released by damaged and destroyed cardiomyocytes, resulting in greatly elevated concentrations in the blood \[[@r32]\]. Increased levels of cTnI have been reported in dogs with mitral insufficiency \[[@r27]\], filariasis \[[@r3]\], atrioventricular block \[[@r29]\], cardiac hemangiosarcoma \[[@r22]\], and administration of doxorubicin \[[@r25]\]. Therefore, it has been concluded that a high cTnI concentration in the blood is not only caused by infarct necrosis of the cardiomyocytes, but also by a variety of heart lesions that induce myocardial injury \[[@r11]\].

In previous studies, myocardial fibrosis formation of the entire ventricle was confirmed microscopically in an animal model that involved high-frequency stimulation of the heart \[[@r6], [@r12]\]. Fibrosis of the ventricular muscle tissue is formed as a scar to replace necrotic cardiomyocytes after a myocardial injury \[[@r6]\]. It has also been shown that injury-associated features such as cellular elongation, myofibril misalignment, sarcomere disassembly, and disappearance of cardiomyocytes occur before the onset of myocardial fibrosis \[[@r23]\]. One of these factors that precede fibrosis is a tachycardia-induced reduction in coronary blood flow, i.e., myocardial ischemia \[[@r14]\]. Furthermore, a direct RAAS involvement in the fibrosis formation has already been demonstrated. Stimulation of AT1 receptors by ANG II upregulates the expression of transforming growth factor-β1 in the cardiac tissue, stimulates collagen accumulation, inhibits the activity of enzymes that degrade the extracellular matrix, enhances the proliferation of fibroblasts, and induces inflammatory responses, all of which may be responsible for myocardial fibrosis \[[@r6], [@r21]\]. In the present study, we could not visualize the development of myocardial fibrosis and the preceding myocardial injury because we did not perform histopathological examinations. However, an increase in cTnI, a biomarker of myocardial injury, was observed after RAP in the Control group, suggesting the occurrence of an injury in the canine ventricular muscles, as reported previously \[[@r6], [@r12]\]. By contrast, no increase in cTnI was observed after RAP in the Telmisartan group. Telmisartan has been shown to ameliorate the reduced blood flow in coronary arteries via activation of AT1 receptors \[[@r34]\]. It was suggested that telmisartan protects myocardial cells against injury by alleviating myocardial ischemia. This is in agreement with the results of the present study; however, a direct inhibition of AT1 receptor-mediated responses, including activation of extracellular matrix-degrading enzymes and proliferation of myocardial fibroblasts, may also have contributed to the inhibitory effects of telmisartan on RAP-induced fibrosis in the current study. Besides AT1 receptor activation, ANG II also stimulates AT2 receptors that act antagonistically to AT1 receptor-mediated responses \[[@r24], [@r33]\]. ARBs cause an elevation in ANG II concentration in the blood via a feedback mechanism involving the blockade of AT1 receptors, resulting in the predominant activity of AT2 receptors \[[@r24], [@r33]\]. Therefore, administration of telmisartan might have suppressed myocardial injury by blocking the AT1 receptor-mediated responses and enhancing the AT2 receptor-mediated responses.

In the present study, the ventricular systolic function was assessed by echocardiography. Generally, a reduced FS is considered to be caused by a decreased preload, an enhanced afterload, or a reduced systolic function of the left ventricle \[[@r7]\]. In the present study, the FS decreased after atrial stimulation in both the Control and the Telmisartan group. However, the reduction in FS was less marked in the Telmisartan group than in the Control group. The parameter FS in both groups largely depended on LVIDs variations. A significant increase in LVIDs was observed after RAP in the Control group but not in the Telmisartan group. These findings suggest that a myocardial injury indicated by an increase in cTnI concentration in the blood is directly associated with the changes in LVIDs and the decrease in left-ventricular contractility in the Control group. Since the myocardial injury was controlled in the Telmisartan group, it is considered that the cardiac contractility was maintained and the LVIDs were largely maintained as compared with the Control group. Moreover, the decrease in blood pressure observed in the Telmisartan group in this study indicated a decrease in afterload probably due to the blockade of the AT1 receptor effect, which may also have contributed to the increase in FS. Our data suggest that telmisartan suppresses the decrease in FS by the interaction of two factors: suppression of the myocardial injury and reduction of the afterload. In the present study, the ratio PEP/ET was increased in both the Control and the Telmisartan group, although the change was less marked in the Telmisartan group. The PEP/ET ratio was also utilized as an index to evaluate the ventricular systolic function with an increase or decrease in this index representing a reduced or enhanced systolic function, respectively \[[@r7]\]. The effect of telmisartan on PEP/ET is considered to be held by maintenance of ventricular contractility, similarly to the interpretation of its effect on FS. Likewise, SV and CO decreased in the Control group after RAP stimulation, but both parameters were maintained in the Telmisartan group at baseline levels due to the preventive effects of telmisartan on the ventricular systolic dysfunction.

A limitation of the present study is the difference in pathophysiology between our animal model of SVTA and clinical cases. The SVTA model in this study was produced by applying RAP in healthy young beagles. In clinical cases, the dogs with SVTA are older than the model dogs and often have valvular diseases, such as mitral and tricuspid regurgitation \[[@r15]\]. Therefore, prospective studies are necessary to be conducted in clinical cases on the basis of the results from our study.

In conclusion, the present study demonstrated that telmisartan suppressed myocardial injury and reduced ventricular systolic dysfunction in a canine model of SVTA. Therefore, telmisartan may be a promising novel drug for SVTA in dogs, provided that blood pressure reduction is carefully monitored.
